Related Experiment Videos
Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy
R B Stricker1, B Barlogie, D D Kiprov
1Department of Medicine, California Pacific Medical Center, San Francisco.
The Journal of Rheumatology
|February 1, 1994
Summary
Interferon-alpha therapy can trigger autoimmune disorders. A multiple myeloma patient developed a fatal bleeding disorder due to antibodies against factor VIII after this treatment, highlighting a need for further research.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Interferon-alpha (IFN-alpha) is used therapeutically but linked to autoimmune complications.
- Autologous bone marrow transplantation is a treatment for multiple myeloma.
Observation:
- A patient with multiple myeloma received chronic IFN-alpha treatment post-transplantation.
- This patient developed an inhibitor antibody against factor VIII coagulant protein (FVIIIC).
Findings:
- The FVIIIC inhibitor antibody led to a severe, fatal hemorrhagic diathesis.
- This case illustrates a specific autoimmune complication associated with IFN-alpha therapy.
Implications:
- The link between IFN-alpha treatment and autoimmune disorders requires broader recognition.
- Further investigation into IFN-alpha-induced autoimmunity is warranted, particularly in hematologic malignancies.